Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways

Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based immunotherapy has gained broad attention for its unique immunological character of tumor identification and eradication and low risk of graft-versus-hos...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 16; no. 7; p. 939
Main Authors Zang, Jing, Mei, Yijun, Zhu, Shiguo, Yin, Shaoping, Feng, Nianping, Ci, Tianyuan, Lyu, Yaqi
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 14.07.2024
Subjects
Adapter proteins
Antibodies
Antigens
Bone marrow
Cancer therapies
Chemotherapy
Clinical medicine
Cytokines
Cytotoxicity
drug delivery system
Drug delivery systems
exosomes
Immunotherapy
Kinases
Ligands
Lymphatic system
Lymphocytes
NK cell activation
Radiation therapy
Side effects
tumor immunity
Tumor necrosis factor-TNF
tumor immunity
drug delivery system
exosomes
NK cell activation
Online AccessGet full text

Cover

Abstract Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based immunotherapy has gained broad attention for its unique immunological character of tumor identification and eradication and low risk of graft-versus-host disease and cytokine storm. With the cooperation of a drug delivery system (DDS), NK cells activate tumoricidal activity by adjusting the balance of the activating and inhibitory signals on their surface after drug-loaded DDS administration. Moreover, NK cells or NK-derived exosomes can also be applied as drug carriers for distinct modification to promote NK activation and exert anti-tumor effects. In this review, we first introduce the source and classification of NK cells and describe the common activating and inhibitory receptors on their surface. Then, we summarize the strategies for activating NK cells in vivo through various DDSs. Finally, the application prospects of NK cells in tumor immunotherapy are also discussed.
AbstractList Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based immunotherapy has gained broad attention for its unique immunological character of tumor identification and eradication and low risk of graft-versus-host disease and cytokine storm. With the cooperation of a drug delivery system (DDS), NK cells activate tumoricidal activity by adjusting the balance of the activating and inhibitory signals on their surface after drug-loaded DDS administration. Moreover, NK cells or NK-derived exosomes can also be applied as drug carriers for distinct modification to promote NK activation and exert anti-tumor effects. In this review, we first introduce the source and classification of NK cells and describe the common activating and inhibitory receptors on their surface. Then, we summarize the strategies for activating NK cells in vivo through various DDSs. Finally, the application prospects of NK cells in tumor immunotherapy are also discussed.
Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based immunotherapy has gained broad attention for its unique immunological character of tumor identification and eradication and low risk of graft-versus-host disease and cytokine storm. With the cooperation of a drug delivery system (DDS), NK cells activate tumoricidal activity by adjusting the balance of the activating and inhibitory signals on their surface after drug-loaded DDS administration. Moreover, NK cells or NK-derived exosomes can also be applied as drug carriers for distinct modification to promote NK activation and exert anti-tumor effects. In this review, we first introduce the source and classification of NK cells and describe the common activating and inhibitory receptors on their surface. Then, we summarize the strategies for activating NK cells in vivo through various DDSs. Finally, the application prospects of NK cells in tumor immunotherapy are also discussed.Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based immunotherapy has gained broad attention for its unique immunological character of tumor identification and eradication and low risk of graft-versus-host disease and cytokine storm. With the cooperation of a drug delivery system (DDS), NK cells activate tumoricidal activity by adjusting the balance of the activating and inhibitory signals on their surface after drug-loaded DDS administration. Moreover, NK cells or NK-derived exosomes can also be applied as drug carriers for distinct modification to promote NK activation and exert anti-tumor effects. In this review, we first introduce the source and classification of NK cells and describe the common activating and inhibitory receptors on their surface. Then, we summarize the strategies for activating NK cells in vivo through various DDSs. Finally, the application prospects of NK cells in tumor immunotherapy are also discussed.
Author Zang, Jing
Zhu, Shiguo
Ci, Tianyuan
Lyu, Yaqi
Mei, Yijun
Feng, Nianping
Yin, Shaoping
Author_xml – sequence: 1
  givenname: Jing
  orcidid: 0009-0004-0746-8922
  surname: Zang
  fullname: Zang, Jing
  organization: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
– sequence: 2
  givenname: Yijun
  orcidid: 0000-0001-7011-4132
  surname: Mei
  fullname: Mei, Yijun
  organization: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
– sequence: 3
  givenname: Shiguo
  surname: Zhu
  fullname: Zhu, Shiguo
  organization: Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
– sequence: 4
  givenname: Shaoping
  orcidid: 0000-0001-7198-1844
  surname: Yin
  fullname: Yin, Shaoping
  organization: School of Pharmacy, Jiangsu Provincial Engineering Research Center of Traditional Chinese Medicine External Medication Development and Application, Nanjing University of Chinese Medicine, Nanjing 210023, China
– sequence: 5
  givenname: Nianping
  orcidid: 0000-0002-5303-2941
  surname: Feng
  fullname: Feng, Nianping
  organization: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
– sequence: 6
  givenname: Tianyuan
  surname: Ci
  fullname: Ci, Tianyuan
  organization: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
– sequence: 7
  givenname: Yaqi
  orcidid: 0000-0002-7182-3472
  surname: Lyu
  fullname: Lyu, Yaqi
  organization: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39065636$$D View this record in MEDLINE/PubMed
BookMark eNptUU1v1DAQtVARLaU_AWSJC5eAPxJvzK3s8lFRQYWWczS2J7tZJXFqO0X77_F2S4UQc_H46b2nmXnPycnoRyTkJWdvpdTs3bSFMIDFOXU2csUWTEv9hJxxrXVRaiFP_upPyUWMO5ZLSl5L_YycZg9VKanOyN03SHOAnn7t-h5D8QEiOrreYoBp_55e0pvg44Q2dXeYYT9vtom2PtAljBYDXQeENOCY6A_sIWVt8nSVySF2bZe_qzBv6Ar7A7SnN5C2v2AfX5CnLfQRLx7ec_Lz08f18ktx_f3z1fLyurCi5qkwCE5aa6QypeNtq6t2wQwa5ip0BhU4VFZIU4NkaLQBoWu0xgLnTKi88Dm5Ovo6D7tmCt0AYd946Jp7wIdNAyEfscdGCahtyQRIUZaianVpWOVMydTCcqYge705ek3B384YUzN00WLfw4h-jo1kdcUFU1pm6ut_qDs_hzFves9iUvDyMFx1ZNl84xiwfRyQs-aQc_PfnLPu1YP7bAZ0j6o_qcrfk2WqOQ
Cites_doi 10.1084/jem.169.6.2233
10.4049/jimmunol.176.7.4331
10.2217/fon-2020-0351
10.1084/jem.20150792
10.3389/fimmu.2019.00909
10.1038/nrc3239
10.4049/jimmunol.178.7.4011
10.1021/jacs.1c11498
10.1002/adfm.202202603
10.1038/s41568-021-00347-z
10.1038/s41571-018-0112-1
10.1021/acsnano.2c07861
10.1002/eji.1830050208
10.1186/s40364-018-0116-0
10.1016/j.semcdb.2015.02.009
10.3390/ijms21093233
10.1053/j.gastro.2021.12.281
10.1016/j.phymed.2020.153402
10.1002/smll.201900903
10.4049/jimmunol.0900284
10.1016/j.mattod.2022.09.009
10.1002/adma.202109354
10.1016/j.biomaterials.2014.08.029
10.3390/cells10051020
10.1186/1479-5876-7-82
10.1080/028418698430566
10.1309/AJCPWGG69MCZOWMM
10.3389/fimmu.2019.01179
10.1021/acsnano.1c00033
10.1136/jitc-2020-002193
10.1002/advs.202201135
10.1182/bloodadvances.2020003458
10.1158/2159-8290.CD-20-0655
10.1038/nnano.2017.54
10.1186/s13045-018-0571-y
10.1016/j.biomaterials.2012.04.041
10.1038/nri3667
10.1038/nri3818
10.1016/j.biomaterials.2022.121371
10.1002/ijc.2910160204
10.1158/0008-5472.CAN-07-6611
10.3389/fimmu.2022.1087689
10.4049/jimmunol.155.12.5803
10.3389/fimmu.2019.01416
10.3322/caac.21763
10.1016/j.jaci.2016.04.025
10.1016/j.nano.2016.07.009
10.1016/j.mtnano.2021.100151
10.1002/adma.201907568
10.1016/j.biomaterials.2015.11.001
10.3389/fimmu.2016.00152
10.1002/adma.201902542
10.3390/biomedicines12040919
10.1080/10717544.2022.2094498
10.1038/cmi.2013.10
10.1016/j.biomaterials.2015.02.068
10.1016/j.semcancer.2021.05.011
10.3390/cancers15082323
10.1007/s12026-015-8664-y
10.1016/j.mam.2020.100870
10.1073/pnas.1513456112
10.1021/jacs.1c02537
10.3389/fimmu.2017.00465
10.1002/JLB.5MIR0917-351R
10.1016/j.addr.2022.114394
10.1021/acsami.0c16357
10.1186/s12967-018-1507-6
10.1084/jem.20090681
10.1016/j.jconrel.2022.03.021
10.1002/adma.202000020
10.1039/C8BM00588E
10.1186/s13045-020-01014-w
10.1158/1535-7163.MCT-05-0014
10.1038/s41573-019-0052-1
10.4049/jimmunol.0901935
10.1038/s41568-019-0186-9
10.1021/acs.nanolett.9b02448
10.1038/nri3799
10.1021/acsnano.3c03456
10.1021/acs.bioconjchem.9b00048
10.3390/cancers13163994
10.1038/nrclinonc.2015.120
10.1016/S0952-7915(02)00337-0
10.1002/anie.202106730
10.1021/acsami.1c03709
10.1111/j.1600-065X.2008.00660.x
10.1158/0008-5472.CAN-12-3558
10.1080/20013078.2017.1294368
10.1056/NEJMoa1910607
10.1038/s41375-019-0613-7
10.1038/gt.2012.88
10.3389/fimmu.2022.1045316
10.1002/iid3.190
10.1038/s41589-020-0622-x
10.1016/j.cell.2017.01.017
10.1039/C7PY01556A
10.1182/blood-2004-12-4802
10.1038/s41571-020-0426-7
10.1002/adma.202206915
10.1002/anie.201914453
10.1016/j.ebiom.2020.102975
10.1038/nrc.2015.5
10.1021/acs.nanolett.7b03186
10.1016/j.semcancer.2022.03.026
10.1002/adma.201804395
10.1002/adfm.201900773
10.1038/s41598-020-59082-4
10.4049/jimmunol.169.8.4279
10.3389/fimmu.2013.00076
10.1021/acscentsci.8b00552
10.1016/j.blre.2023.101073
10.1186/s13045-020-00998-9
10.3390/cancers11101560
10.1172/JCI45816
10.1186/s13045-021-01083-5
10.3109/14653249.2012.671519
10.1172/JCI90387
10.1038/s41467-019-12998-6
10.1016/j.cell.2019.04.041
10.1021/acsnano.0c02207
10.1016/j.jconrel.2022.01.049
10.1002/advs.202103836
10.1084/jem.20181454
10.1186/s40364-022-00364-6
10.1002/adma.202208277
10.1158/0008-5472.CAN-16-1536
10.3389/fimmu.2016.00091
10.1186/s12943-022-01672-z
10.3389/fimmu.2015.00368
10.1016/S1470-2045(15)00223-5
10.1002/adma.202108167
10.1182/blood.V90.3.1109
10.1038/nrc3958
10.1002/adfm.202004550
ContentType Journal Article
Copyright 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID NPM
AAYXX
CITATION
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOA
DOI 10.3390/pharmaceutics16070939
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Databases
ProQuest One Community College
ProQuest Central
ProQuest Central Student
Research Library Prep
Research Library
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
PubMed
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_62a8c402a324425f94b05db4067c106a
10_3390_pharmaceutics16070939
39065636
Genre Journal Article
Review
GrantInformation_xml – fundername: Program for Shanghai High-Level Local University Innovation Team
  grantid: SZY20220315
– fundername: Shanghai Rising-Star Program
  grantid: 21QA1408800
– fundername: National Natural Science Foundation of China
  grantid: 82173984
GroupedDBID ---
3V.
53G
5VS
8G5
AADQD
ABDBF
ABUWG
ACGFO
ACIHN
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
M48
MK0
MODMG
M~E
NPM
OK1
P6G
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TR2
TUS
AAYXX
CITATION
7XB
8FK
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c281t-bead3ccb36b4d1ff95f70beb0d5edbe6ade6c23b8a30eb9ba298ecbca11026003
IEDL.DBID M48
ISSN 1999-4923
IngestDate Tue Oct 22 15:13:57 EDT 2024
Sat Oct 26 04:31:21 EDT 2024
Thu Oct 10 22:37:00 EDT 2024
Thu Sep 26 21:17:56 EDT 2024
Sat Nov 02 12:22:41 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords tumor immunity
drug delivery system
exosomes
NK cell activation
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c281t-bead3ccb36b4d1ff95f70beb0d5edbe6ade6c23b8a30eb9ba298ecbca11026003
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-5303-2941
0000-0002-7182-3472
0000-0001-7011-4132
0000-0001-7198-1844
0009-0004-0746-8922
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics16070939
PMID 39065636
PQID 3085032140
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_62a8c402a324425f94b05db4067c106a
proquest_miscellaneous_3085120693
proquest_journals_3085032140
crossref_primary_10_3390_pharmaceutics16070939
pubmed_primary_39065636
PublicationCentury 2000
PublicationDate 2024-Jul-14
PublicationDateYYYYMMDD 2024-07-14
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-Jul-14
  day: 14
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2024
Publisher MDPI AG
Publisher_xml – name: MDPI AG
References Peng (ref_15) 2022; 9
Herberman (ref_20) 1975; 16
He (ref_39) 2021; 31
Im (ref_125) 2020; 32
Morvan (ref_31) 2016; 16
Papayannakos (ref_113) 2013; 20
Khushalani (ref_98) 2020; 16
Liu (ref_112) 2020; 382
Angelo (ref_72) 2015; 62
Li (ref_119) 2018; 4
Liu (ref_11) 2021; 80
ref_132
Myers (ref_71) 2021; 18
Kim (ref_95) 2020; 12
Wagner (ref_28) 2017; 127
ref_18
Klein (ref_48) 2014; 14
DeVita (ref_5) 2008; 68
Zhang (ref_94) 2022; 34
Cozar (ref_70) 2021; 11
Jong (ref_134) 2017; 6
ref_22
Cho (ref_61) 2009; 29
Portevin (ref_102) 2009; 7
ref_122
ref_121
Cheng (ref_62) 2013; 10
Merino (ref_50) 2023; 60
Gowd (ref_13) 2022; 86
Tong (ref_116) 2022; 21
Martinet (ref_110) 2015; 15
ref_27
ref_26
Yang (ref_118) 2019; 15
Chandrasekaran (ref_126) 2016; 77
Meng (ref_124) 2022; 32
Freud (ref_25) 2013; 140
Sharma (ref_16) 2017; 168
Shimasaki (ref_115) 2012; 14
Burga (ref_130) 2019; 30
Pan (ref_43) 2021; 143
Liu (ref_84) 2022; 345
Zheng (ref_77) 2019; 31
Weng (ref_133) 2021; 74
Wu (ref_128) 2018; 6
Lin (ref_100) 2015; 112
Zhang (ref_135) 2022; 9
Rojas (ref_104) 2015; 52
Liau (ref_41) 2018; 16
Mitwasi (ref_107) 2020; 10
Lanier (ref_23) 1989; 169
Huang (ref_42) 2017; 8
Yang (ref_75) 2022; 144
ref_89
ref_85
Poupot (ref_101) 2016; 12
Jang (ref_129) 2012; 33
Gao (ref_88) 2020; 32
Chang (ref_114) 2013; 73
Qian (ref_90) 2019; 19
Zhang (ref_68) 2015; 212
Quintarelli (ref_123) 2020; 34
Pardoll (ref_3) 2012; 12
Zhan (ref_91) 2023; 35
Kiessling (ref_19) 1975; 5
ref_58
Song (ref_78) 2017; 17
Gray (ref_73) 2020; 16
Han (ref_51) 2022; 343
ref_52
Gong (ref_55) 2021; 14
Zamai (ref_32) 2007; 178
Wang (ref_83) 2022; 34
Jiang (ref_80) 2021; 13
Kim (ref_86) 2019; 29
Strobel (ref_7) 2019; 16
Hinterberger (ref_81) 2019; 10
Greening (ref_131) 2015; 40
Roche (ref_49) 2015; 15
Yilmaz (ref_120) 2020; 13
Li (ref_45) 2020; 59
Dubois (ref_99) 2021; 9
Ebert (ref_34) 2006; 176
Nguyen (ref_65) 2002; 169
Siegel (ref_1) 2023; 73
Hu (ref_79) 2022; 17
Gauthier (ref_44) 2019; 177
Tohme (ref_2) 2017; 77
Wang (ref_92) 2021; 15
Dumoutier (ref_59) 2009; 183
Perry (ref_82) 2020; 14
Teng (ref_117) 2022; 162
Zhu (ref_40) 2023; 17
Liao (ref_97) 2021; 60
Goldberg (ref_12) 2019; 19
Yang (ref_53) 2022; 187
Pesce (ref_74) 2017; 139
Owen (ref_35) 1995; 155
Wei (ref_87) 2022; 34
ref_111
ref_30
Shimasaki (ref_24) 2020; 19
Sivori (ref_17) 2021; 80
ref_38
Surace (ref_106) 2021; 5
ref_37
Schaue (ref_9) 2015; 12
Prager (ref_29) 2019; 216
Aqbi (ref_36) 2018; 103
Fuchs (ref_60) 2005; 106
Allen (ref_67) 2021; 21
Tomala (ref_63) 2009; 183
ref_105
Li (ref_93) 2023; 17
ref_108
Liu (ref_21) 2021; 14
Koene (ref_56) 1997; 90
Yim (ref_103) 2014; 35
Xue (ref_127) 2017; 12
ref_47
ref_46
Porter (ref_109) 2018; 11
Hydes (ref_64) 2018; 6
Li (ref_10) 2022; 29
Barker (ref_4) 2015; 15
Hellstrand (ref_96) 1998; 37
Long (ref_69) 2008; 224
Mamessier (ref_66) 2011; 121
Sullivan (ref_6) 2015; 16
ref_8
Vivier (ref_54) 2002; 14
Mei (ref_14) 2022; 60
Ji (ref_76) 2019; 31
Lyu (ref_33) 2005; 4
Brandt (ref_57) 2009; 206
References_xml – volume: 169
  start-page: 2233
  year: 1989
  ident: ref_23
  article-title: Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.169.6.2233
  contributor:
    fullname: Lanier
– volume: 176
  start-page: 4331
  year: 2006
  ident: ref_34
  article-title: Homing and function of human skin γδ T cells and NK cells:: Relevance for tumor surveillance
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.176.7.4331
  contributor:
    fullname: Ebert
– volume: 16
  start-page: 2165
  year: 2020
  ident: ref_98
  article-title: Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
  publication-title: Future Oncol.
  doi: 10.2217/fon-2020-0351
  contributor:
    fullname: Khushalani
– volume: 29
  start-page: 89
  year: 2009
  ident: ref_61
  article-title: Expansion and activation of natural killer cells for cancer immunotherapy
  publication-title: Korean J. Lab. Med.
  contributor:
    fullname: Cho
– volume: 212
  start-page: 2165
  year: 2015
  ident: ref_68
  article-title: DNAM-1 controls NK cell activation via an ITT-like motif
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20150792
  contributor:
    fullname: Zhang
– ident: ref_58
  doi: 10.3389/fimmu.2019.00909
– volume: 12
  start-page: 252
  year: 2012
  ident: ref_3
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: Pardoll
– volume: 178
  start-page: 4011
  year: 2007
  ident: ref_32
  article-title: NK cells and cancer
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.178.7.4011
  contributor:
    fullname: Zamai
– volume: 144
  start-page: 3863
  year: 2022
  ident: ref_75
  article-title: Photophosphatidylserine guides natural killer cell photoimmunotherapy via Tim-3
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.1c11498
  contributor:
    fullname: Yang
– volume: 32
  start-page: 2202603
  year: 2022
  ident: ref_124
  article-title: In situ activated NK cell as bio-orthogonal targeted live-cell nanocarrier augmented solid tumor immunotherapy
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.202202603
  contributor:
    fullname: Meng
– volume: 21
  start-page: 345
  year: 2021
  ident: ref_67
  article-title: Systemic immunity in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-021-00347-z
  contributor:
    fullname: Allen
– volume: 16
  start-page: 11
  year: 2019
  ident: ref_7
  article-title: Optimizing the outcomes of pancreatic cancer surgery
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-018-0112-1
  contributor:
    fullname: Strobel
– volume: 17
  start-page: 322
  year: 2023
  ident: ref_93
  article-title: Macrophage membrane-coated nano- gemcitabine promotes lymphocyte infiltration and synergizes AntiPD-L1 to restore the tumoricidal function
  publication-title: Acs Nano
  doi: 10.1021/acsnano.2c07861
  contributor:
    fullname: Li
– volume: 5
  start-page: 112
  year: 1975
  ident: ref_19
  article-title: “Natural” killer cells in the mouse. I. cytotoxic cells with specificity for mouse moloney leukemia cells. specificity and distribution according to genotype
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830050208
  contributor:
    fullname: Kiessling
– ident: ref_108
  doi: 10.1186/s40364-018-0116-0
– volume: 40
  start-page: 72
  year: 2015
  ident: ref_131
  article-title: Exosomes and their roles in immune regulation and cancer
  publication-title: Semin. Cell Dev. Biol.
  doi: 10.1016/j.semcdb.2015.02.009
  contributor:
    fullname: Greening
– ident: ref_8
  doi: 10.3390/ijms21093233
– volume: 162
  start-page: 1319
  year: 2022
  ident: ref_117
  article-title: Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.12.281
  contributor:
    fullname: Teng
– volume: 80
  start-page: 153402
  year: 2021
  ident: ref_11
  article-title: Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2020.153402
  contributor:
    fullname: Liu
– volume: 15
  start-page: 1900903
  year: 2019
  ident: ref_118
  article-title: Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy
  publication-title: Small
  doi: 10.1002/smll.201900903
  contributor:
    fullname: Yang
– volume: 183
  start-page: 4904
  year: 2009
  ident: ref_63
  article-title: In vivo expansion of activated naive CD8(+) T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0900284
  contributor:
    fullname: Tomala
– volume: 60
  start-page: 52
  year: 2022
  ident: ref_14
  article-title: A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy
  publication-title: Mater. Today
  doi: 10.1016/j.mattod.2022.09.009
  contributor:
    fullname: Mei
– volume: 34
  start-page: 2109354
  year: 2022
  ident: ref_83
  article-title: The development of chiral nanoparticles to target NK cells and CD8(+) T cells for cancer immunotherapy
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202109354
  contributor:
    fullname: Wang
– volume: 35
  start-page: 9912
  year: 2014
  ident: ref_103
  article-title: A self-assembled polymeric micellar immunomodulator for cancer treatment based on cationic amphiphilic polymers
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2014.08.029
  contributor:
    fullname: Yim
– ident: ref_105
  doi: 10.3390/cells10051020
– volume: 7
  start-page: 82
  year: 2009
  ident: ref_102
  article-title: Regulatory activity of azabisphosphonate-capped dendrimers on human CD4(+) T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-7-82
  contributor:
    fullname: Portevin
– volume: 37
  start-page: 347
  year: 1998
  ident: ref_96
  article-title: Histamine and cytokine therapy
  publication-title: Acta Oncol.
  doi: 10.1080/028418698430566
  contributor:
    fullname: Hellstrand
– volume: 140
  start-page: 853
  year: 2013
  ident: ref_25
  article-title: Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia
  publication-title: Am. J. Clin. Pathol.
  doi: 10.1309/AJCPWGG69MCZOWMM
  contributor:
    fullname: Freud
– ident: ref_26
  doi: 10.3389/fimmu.2019.01179
– volume: 15
  start-page: 5405
  year: 2021
  ident: ref_92
  article-title: Oxygen-delivering polyfluorocarbon nanovehicles improve tumor oxygenation and potentiate photodynamic-mediated antitumor immunity
  publication-title: Acs Nano
  doi: 10.1021/acsnano.1c00033
  contributor:
    fullname: Wang
– volume: 9
  start-page: e002193
  year: 2021
  ident: ref_99
  article-title: Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: Implications for combination therapy with antitumor antibodies
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-002193
  contributor:
    fullname: Dubois
– volume: 9
  start-page: 2201135
  year: 2022
  ident: ref_135
  article-title: Conscription of immune cells by light-activatable silencing NK-derived exosome (LASNEO) for synergetic tumor eradication
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202201135
  contributor:
    fullname: Zhang
– volume: 5
  start-page: 26
  year: 2021
  ident: ref_106
  article-title: Polarized mitochondria as guardians of NK cell fitness
  publication-title: Blood Adv.
  doi: 10.1182/bloodadvances.2020003458
  contributor:
    fullname: Surace
– volume: 11
  start-page: 34
  year: 2021
  ident: ref_70
  article-title: Tumor-infiltrating natural killer cells
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-20-0655
  contributor:
    fullname: Cozar
– volume: 12
  start-page: 692
  year: 2017
  ident: ref_127
  article-title: Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/nnano.2017.54
  contributor:
    fullname: Xue
– volume: 11
  start-page: 35
  year: 2018
  ident: ref_109
  article-title: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-018-0571-y
  contributor:
    fullname: Porter
– volume: 33
  start-page: 5584
  year: 2012
  ident: ref_129
  article-title: The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2012.04.041
  contributor:
    fullname: Jang
– volume: 14
  start-page: 377
  year: 2014
  ident: ref_48
  article-title: Positive and negative selection of the T cell repertoire: What thymocytes see (and don’t see)
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3667
  contributor:
    fullname: Klein
– volume: 15
  start-page: 203
  year: 2015
  ident: ref_49
  article-title: The ins and outs of MHC class II-mediated antigen processing and presentation
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3818
  contributor:
    fullname: Roche
– ident: ref_89
  doi: 10.1016/j.biomaterials.2022.121371
– volume: 16
  start-page: 216
  year: 1975
  ident: ref_20
  article-title: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.2910160204
  contributor:
    fullname: Herberman
– volume: 68
  start-page: 8643
  year: 2008
  ident: ref_5
  article-title: A history of cancer chemotherapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-6611
  contributor:
    fullname: DeVita
– ident: ref_46
  doi: 10.3389/fimmu.2022.1087689
– volume: 155
  start-page: 5803
  year: 1995
  ident: ref_35
  article-title: Inducible binding of bioactive cathepsin-G to the cell-surface of neutrophils—A novel mechanism for mediating extracellular catalytic activity of cathepsin-G
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.155.12.5803
  contributor:
    fullname: Owen
– ident: ref_27
  doi: 10.3389/fimmu.2019.01416
– volume: 73
  start-page: 17
  year: 2023
  ident: ref_1
  article-title: Cancer statistics, 2023
  publication-title: CA-Cancer J. Clin.
  doi: 10.3322/caac.21763
  contributor:
    fullname: Siegel
– volume: 139
  start-page: 335
  year: 2017
  ident: ref_74
  article-title: Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
  publication-title: J. Allergy Clin. Immun.
  doi: 10.1016/j.jaci.2016.04.025
  contributor:
    fullname: Pesce
– volume: 12
  start-page: 2321
  year: 2016
  ident: ref_101
  article-title: Poly(phosphorhydrazone) dendrimers: Yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma
  publication-title: Nanomed.-Nano Technol.
  doi: 10.1016/j.nano.2016.07.009
  contributor:
    fullname: Poupot
– volume: 17
  start-page: 100151
  year: 2022
  ident: ref_79
  article-title: Simultaneous delivery of immune stimulatory gene and checkpoint blocker via targeted nanoparticles to strengthen antitumor immunity
  publication-title: Mater. Today Nano
  doi: 10.1016/j.mtnano.2021.100151
  contributor:
    fullname: Hu
– volume: 32
  start-page: 1907568
  year: 2020
  ident: ref_88
  article-title: Selenium-containing nanoparticles combine the NK cells mediated immunotherapy with radiotherapy and chemotherapy
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201907568
  contributor:
    fullname: Gao
– volume: 77
  start-page: 66
  year: 2016
  ident: ref_126
  article-title: Super natural killer cells that target metastases in the tumor draining lymph nodes
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2015.11.001
  contributor:
    fullname: Chandrasekaran
– ident: ref_52
  doi: 10.3389/fimmu.2016.00152
– volume: 31
  start-page: 1902542
  year: 2019
  ident: ref_77
  article-title: In situ modification of the tumor cell surface with immunomodulating nanoparticles for effective suppression of tumor growth in mice
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201902542
  contributor:
    fullname: Zheng
– ident: ref_47
  doi: 10.3390/biomedicines12040919
– volume: 29
  start-page: 2130
  year: 2022
  ident: ref_10
  article-title: Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: A review
  publication-title: Drug Deliv.
  doi: 10.1080/10717544.2022.2094498
  contributor:
    fullname: Li
– volume: 10
  start-page: 230
  year: 2013
  ident: ref_62
  article-title: NK cell-based immunotherapy for malignant diseases
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/cmi.2013.10
  contributor:
    fullname: Cheng
– volume: 52
  start-page: 494
  year: 2015
  ident: ref_104
  article-title: Polyethylenimine-coated SPIONs trigger macrophage activation through TLR-4 signaling and ROS production and modulate podosome dynamics
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2015.02.068
  contributor:
    fullname: Rojas
– volume: 74
  start-page: 105
  year: 2021
  ident: ref_133
  article-title: Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2021.05.011
  contributor:
    fullname: Weng
– ident: ref_30
  doi: 10.3390/cancers15082323
– volume: 62
  start-page: 341
  year: 2015
  ident: ref_72
  article-title: Practical NK cell phenotyping and variability in healthy adults
  publication-title: Immunol. Res.
  doi: 10.1007/s12026-015-8664-y
  contributor:
    fullname: Angelo
– volume: 80
  start-page: 100870
  year: 2021
  ident: ref_17
  article-title: NK cells and ILCs in tumor immunotherapy
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2020.100870
  contributor:
    fullname: Sivori
– volume: 112
  start-page: 10611
  year: 2015
  ident: ref_100
  article-title: A common glycan structure on immunoglobulin G for enhancement of effector functions
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1513456112
  contributor:
    fullname: Lin
– volume: 143
  start-page: 8116
  year: 2021
  ident: ref_43
  article-title: Mild magnetic hyperthermia-activated innate immunity for liver cancer therapy
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.1c02537
  contributor:
    fullname: Pan
– ident: ref_121
  doi: 10.3389/fimmu.2017.00465
– volume: 103
  start-page: 1219
  year: 2018
  ident: ref_36
  article-title: IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression
  publication-title: J. Leukoc. Biol.
  doi: 10.1002/JLB.5MIR0917-351R
  contributor:
    fullname: Aqbi
– volume: 187
  start-page: 114394
  year: 2022
  ident: ref_53
  article-title: Cell-based drug delivery systems and their in vivo fate
  publication-title: Adv. Drug Deliver. Rev.
  doi: 10.1016/j.addr.2022.114394
  contributor:
    fullname: Yang
– volume: 12
  start-page: 56731
  year: 2020
  ident: ref_95
  article-title: Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.0c16357
  contributor:
    fullname: Kim
– volume: 16
  start-page: 142
  year: 2018
  ident: ref_41
  article-title: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-018-1507-6
  contributor:
    fullname: Liau
– volume: 206
  start-page: 1495
  year: 2009
  ident: ref_57
  article-title: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20090681
  contributor:
    fullname: Brandt
– volume: 345
  start-page: 306
  year: 2022
  ident: ref_84
  article-title: Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2022.03.021
  contributor:
    fullname: Liu
– volume: 32
  start-page: 2000020
  year: 2020
  ident: ref_125
  article-title: Harnessing the formation of natural killer-tumor cell immunological synapses for enhanced therapeutic effect in solid tumors
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202000020
  contributor:
    fullname: Im
– volume: 6
  start-page: 2714
  year: 2018
  ident: ref_128
  article-title: Magnetic delivery of Fe3O4@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment
  publication-title: Biomater. Sci.
  doi: 10.1039/C8BM00588E
  contributor:
    fullname: Wu
– volume: 14
  start-page: 7
  year: 2021
  ident: ref_21
  article-title: NK cell-based cancer immunotherapy: From basic biology to clinical development
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-01014-w
  contributor:
    fullname: Liu
– volume: 4
  start-page: 1205
  year: 2005
  ident: ref_33
  article-title: The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-05-0014
  contributor:
    fullname: Lyu
– volume: 19
  start-page: 200
  year: 2020
  ident: ref_24
  article-title: NK cells for cancer immunotherapy
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-019-0052-1
  contributor:
    fullname: Shimasaki
– volume: 183
  start-page: 6579
  year: 2009
  ident: ref_59
  article-title: The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against citrobacter rodentium
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0901935
  contributor:
    fullname: Dumoutier
– volume: 19
  start-page: 587
  year: 2019
  ident: ref_12
  article-title: Improving cancer immunotherapy through nanotechnology
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0186-9
  contributor:
    fullname: Goldberg
– volume: 19
  start-page: 8409
  year: 2019
  ident: ref_90
  article-title: Biodegradable mesoporous silica achieved via carbon nanodots-incorporated framework swelling for debris-mediated photothermal synergistic immunotherapy
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.9b02448
  contributor:
    fullname: Qian
– volume: 15
  start-page: 243
  year: 2015
  ident: ref_110
  article-title: Balancing natural killer cell activation through paired receptors
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3799
  contributor:
    fullname: Martinet
– volume: 17
  start-page: 16770
  year: 2023
  ident: ref_40
  article-title: Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy
  publication-title: Acs Nano
  doi: 10.1021/acsnano.3c03456
  contributor:
    fullname: Zhu
– volume: 30
  start-page: 552
  year: 2019
  ident: ref_130
  article-title: Designing magnetically responsive biohybrids composed of cord blood-derived natural killer cells and iron oxide nanoparticles
  publication-title: Bioconjugate Chem.
  doi: 10.1021/acs.bioconjchem.9b00048
  contributor:
    fullname: Burga
– ident: ref_85
  doi: 10.3390/cancers13163994
– volume: 12
  start-page: 527
  year: 2015
  ident: ref_9
  article-title: Opportunities and challenges of radiotherapy for treating cancer
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.120
  contributor:
    fullname: Schaue
– volume: 14
  start-page: 306
  year: 2002
  ident: ref_54
  article-title: Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition?
  publication-title: Curr. Opin. Immunol.
  doi: 10.1016/S0952-7915(02)00337-0
  contributor:
    fullname: Vivier
– volume: 60
  start-page: 20888
  year: 2021
  ident: ref_97
  article-title: In vivo tracking of cell viability for adoptive natural killer cell-based immunotherapy by ratiometric NIR-II fluorescence imaging
  publication-title: Angew. Chem. Int. Edit.
  doi: 10.1002/anie.202106730
  contributor:
    fullname: Liao
– volume: 13
  start-page: 22213
  year: 2021
  ident: ref_80
  article-title: Lymph lymph node delivery strategy enables the activation of cytotoxic T lymphocytes and natural killer cells to augment cancer immunotherapy
  publication-title: Acs Appl. Mater. Inter.
  doi: 10.1021/acsami.1c03709
  contributor:
    fullname: Jiang
– volume: 224
  start-page: 70
  year: 2008
  ident: ref_69
  article-title: Negative signaling by inhibitory receptors: The NK cell paradigm
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2008.00660.x
  contributor:
    fullname: Long
– volume: 73
  start-page: 1777
  year: 2013
  ident: ref_114
  article-title: A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-3558
  contributor:
    fullname: Chang
– volume: 6
  start-page: 1294368
  year: 2017
  ident: ref_134
  article-title: Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells
  publication-title: J. Extracell. Vesicles
  doi: 10.1080/20013078.2017.1294368
  contributor:
    fullname: Jong
– volume: 382
  start-page: 545
  year: 2020
  ident: ref_112
  article-title: Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1910607
  contributor:
    fullname: Liu
– volume: 34
  start-page: 1102
  year: 2020
  ident: ref_123
  article-title: Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/s41375-019-0613-7
  contributor:
    fullname: Quintarelli
– volume: 20
  start-page: 581
  year: 2013
  ident: ref_113
  article-title: Understanding lentiviral vector chromatin targeting: Working to reduce insertional mutagenic potential for gene therapy
  publication-title: Gene Ther.
  doi: 10.1038/gt.2012.88
  contributor:
    fullname: Papayannakos
– ident: ref_22
  doi: 10.3389/fimmu.2022.1045316
– volume: 6
  start-page: 34
  year: 2018
  ident: ref_64
  article-title: IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells
  publication-title: Immun. Inflamm. Dis.
  doi: 10.1002/iid3.190
  contributor:
    fullname: Hydes
– volume: 16
  start-page: 1376
  year: 2020
  ident: ref_73
  article-title: Targeted glycan degradation potentiates the anticancer immune response in vivo
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-020-0622-x
  contributor:
    fullname: Gray
– volume: 168
  start-page: 707
  year: 2017
  ident: ref_16
  article-title: Primary, adaptive, and acquired resistance to cancer immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.017
  contributor:
    fullname: Sharma
– volume: 8
  start-page: 6675
  year: 2017
  ident: ref_42
  article-title: Charge-reversible and pH-responsive biodegradable micelles and vesicles from linear-dendritic supramolecular amphiphiles for anticancer drug delivery
  publication-title: Polym. Chem.
  doi: 10.1039/C7PY01556A
  contributor:
    fullname: Huang
– volume: 106
  start-page: 2076
  year: 2005
  ident: ref_60
  article-title: Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44
  publication-title: Blood
  doi: 10.1182/blood-2004-12-4802
  contributor:
    fullname: Fuchs
– volume: 18
  start-page: 85
  year: 2021
  ident: ref_71
  article-title: Exploring the NK cell platform for cancer immunotherapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-020-0426-7
  contributor:
    fullname: Myers
– volume: 34
  start-page: 2206915
  year: 2022
  ident: ref_94
  article-title: A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202206915
  contributor:
    fullname: Zhang
– volume: 59
  start-page: 2700
  year: 2020
  ident: ref_45
  article-title: Diselenide-pemetrexed assemblies for combined cancer immuno-, radio-, and chemotherapies
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.201914453
  contributor:
    fullname: Li
– ident: ref_111
  doi: 10.1016/j.ebiom.2020.102975
– volume: 16
  start-page: 7
  year: 2016
  ident: ref_31
  article-title: NK cells and cancer: You can teach innate cells new tricks
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2015.5
  contributor:
    fullname: Morvan
– volume: 17
  start-page: 6366
  year: 2017
  ident: ref_78
  article-title: Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy
  publication-title: Nano Lett.
  doi: 10.1021/acs.nanolett.7b03186
  contributor:
    fullname: Song
– volume: 86
  start-page: 624
  year: 2022
  ident: ref_13
  article-title: Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.03.026
  contributor:
    fullname: Gowd
– volume: 31
  start-page: 1804395
  year: 2019
  ident: ref_76
  article-title: Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201804395
  contributor:
    fullname: Ji
– volume: 29
  start-page: 1900773
  year: 2019
  ident: ref_86
  article-title: Local immune-triggered surface-modified stem cells for solid tumor immunotherapy
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.201900773
  contributor:
    fullname: Kim
– volume: 10
  start-page: 2141
  year: 2020
  ident: ref_107
  article-title: “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-59082-4
  contributor:
    fullname: Mitwasi
– volume: 169
  start-page: 4279
  year: 2002
  ident: ref_65
  article-title: Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.8.4279
  contributor:
    fullname: Nguyen
– ident: ref_18
  doi: 10.3389/fimmu.2013.00076
– volume: 4
  start-page: 1633
  year: 2018
  ident: ref_119
  article-title: A single-step chemoenzymatic reaction for the construction of antibody-cell conjugates
  publication-title: Acs Cent. Sci.
  doi: 10.1021/acscentsci.8b00552
  contributor:
    fullname: Li
– volume: 60
  start-page: 101073
  year: 2023
  ident: ref_50
  article-title: Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting
  publication-title: Blood Rev.
  doi: 10.1016/j.blre.2023.101073
  contributor:
    fullname: Merino
– volume: 13
  start-page: 168
  year: 2020
  ident: ref_120
  article-title: Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-00998-9
  contributor:
    fullname: Yilmaz
– ident: ref_132
  doi: 10.3390/cancers11101560
– volume: 121
  start-page: 3609
  year: 2011
  ident: ref_66
  article-title: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI45816
  contributor:
    fullname: Mamessier
– volume: 14
  start-page: 73
  year: 2021
  ident: ref_55
  article-title: Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-021-01083-5
  contributor:
    fullname: Gong
– volume: 14
  start-page: 830
  year: 2012
  ident: ref_115
  article-title: A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
  publication-title: Cytotherapy
  doi: 10.3109/14653249.2012.671519
  contributor:
    fullname: Shimasaki
– volume: 127
  start-page: 4042
  year: 2017
  ident: ref_28
  article-title: CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI90387
  contributor:
    fullname: Wagner
– volume: 10
  start-page: 5041
  year: 2019
  ident: ref_81
  article-title: Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-12998-6
  contributor:
    fullname: Hinterberger
– volume: 177
  start-page: 1701
  year: 2019
  ident: ref_44
  article-title: Multifunctional natural killer cell engagers targeting nkp46 trigger protective tumor immunity
  publication-title: Cell
  doi: 10.1016/j.cell.2019.04.041
  contributor:
    fullname: Gauthier
– volume: 14
  start-page: 7200
  year: 2020
  ident: ref_82
  article-title: Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer
  publication-title: Acs Nano
  doi: 10.1021/acsnano.0c02207
  contributor:
    fullname: Perry
– volume: 343
  start-page: 379
  year: 2022
  ident: ref_51
  article-title: Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2022.01.049
  contributor:
    fullname: Han
– volume: 9
  start-page: 2103836
  year: 2022
  ident: ref_15
  article-title: Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy
  publication-title: Adv. Sci.
  doi: 10.1002/advs.202103836
  contributor:
    fullname: Peng
– volume: 216
  start-page: 2113
  year: 2019
  ident: ref_29
  article-title: NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20181454
  contributor:
    fullname: Prager
– ident: ref_122
  doi: 10.1186/s40364-022-00364-6
– volume: 35
  start-page: 2208277
  year: 2023
  ident: ref_91
  article-title: Phosphorous dendron micelles as a nanomedicine platform for cooperative tumor chemoimmunotherapy via synergistic modulation of immune cells
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202208277
  contributor:
    fullname: Zhan
– volume: 77
  start-page: 1548
  year: 2017
  ident: ref_2
  article-title: Surgery for cancer: A trigger for metastases
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-1536
  contributor:
    fullname: Tohme
– ident: ref_37
  doi: 10.3389/fimmu.2016.00091
– volume: 21
  start-page: 206
  year: 2022
  ident: ref_116
  article-title: NK cells and solid tumors: Therapeutic potential and persisting obstacles
  publication-title: Molecular Cancer
  doi: 10.1186/s12943-022-01672-z
  contributor:
    fullname: Tong
– ident: ref_38
  doi: 10.3389/fimmu.2015.00368
– volume: 16
  start-page: 1193
  year: 2015
  ident: ref_6
  article-title: Global cancer surgery: Delivering safe, aff ordable, and timely cancer surgery
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(15)00223-5
  contributor:
    fullname: Sullivan
– volume: 34
  start-page: 2108167
  year: 2022
  ident: ref_87
  article-title: Selenopeptide nanomedicine activates natural killer cells for enhanced tumor chemoimmunotherapy
  publication-title: Adv. Mater.
  doi: 10.1002/adma.202108167
  contributor:
    fullname: Wei
– volume: 90
  start-page: 1109
  year: 1997
  ident: ref_56
  article-title: Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma IIIa-48L/R/H phenotype
  publication-title: Blood
  doi: 10.1182/blood.V90.3.1109
  contributor:
    fullname: Koene
– volume: 15
  start-page: 409
  year: 2015
  ident: ref_4
  article-title: The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3958
  contributor:
    fullname: Barker
– volume: 31
  start-page: 2004550
  year: 2021
  ident: ref_39
  article-title: Pulmonary targeting crosslinked cyclodextrin metal-organic frameworks for lung cancer therapy
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.202004550
  contributor:
    fullname: He
SSID ssj0000331839
Score 2.3576462
SecondaryResourceType review_article
Snippet Immunotherapy has been a research hotspot due to its low side effects, long-lasting efficacy, and wide anti-tumor spectrum. Recently, NK cell-based...
SourceID doaj
proquest
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage 939
SubjectTerms Adapter proteins
Antibodies
Antigens
Bone marrow
Cancer therapies
Chemotherapy
Clinical medicine
Cytokines
Cytotoxicity
drug delivery system
Drug delivery systems
exosomes
Immunotherapy
Kinases
Ligands
Lymphatic system
Lymphocytes
NK cell activation
Radiation therapy
Side effects
tumor immunity
Tumor necrosis factor-TNF
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iyYv4tr6IIJ6stklf8aauIoqyhxW8lUyS6kF2l92u0n_vJOnuKihevKYJDZkvnW_SmS-EHCGlhSiXScjRvYaJqqqwKOy5lRYxy5lW4OrWHh6z26fk7jl9_nLVl80J8_LAfuHOMiYLhUGORM-P-KpEAlGqAf1QrjCc8dQoEl-CKfcN5harwpfscIzrz4av8yPisVVVw1BefHNGTrP_d6LpHM7NCllumSK98DNcJQumv0aOu_4FzQntzSunxif0mHbnItTNOnl_lE5Rg967Yr_wEr2Vbsc05_SCdkeDaZUlNtu7emqKBJZeWRiMaG-agE5duhyOrQe045M4KqSttDOavNCOebNNDe0ikfyQzXiDPN1c965uw_aOhVCxIq5DQCRxpYBnkOi4qkRa5REYiHRqNJhMapMpxqGQPDIgQDJRGAVKIm2w2vZ8kyz2B32zTajgIEEL5ENIwiqGcYjJs1ynkDIjMOgNyOl0scuhl9IoMQSx1il_tE5ALq1JZp2tErZrQHyULT7Kv_ARkL2pQct2e45LboX67BVNUUAOZ49xY9m_JbJvBhPfJ2ZRJnhAtjwQZjPBKSMP5tnOf8xwlywxZEr2wDhO9shiPZqYfWQ6NRw4UH8CkCz8_w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Databases
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge-GCeBNakJFQTw117LzMBXW7rSoQqwhtpd4ij-20B7RZkmxR_j3jxNkVEnD1I4kyY_ub8cw3hHxASAssU3Eo8HgNY11VYZ47v5WREc-40TDkrX1bplfX8Zeb5MY73FofVjnticNGbWrtfOSnwnGruao67PPmZ-iqRrnbVV9C4yE5cD1sRg7mF8vi-87LwoTTWTmm7gi07083d3tXcevY1dCkl38cSgN3_78B53DwXD4hjz1ipGejiJ-SB3b9jBwX4wv6E7raZ1C1J_SYFnsy6v45uV-qgVmDfh2S_sI5nlrGz-k_0TNaNPWUbYnNrmZPRxHI0nOnDg1dTYHodAibw7ldTRdjMEeF8JUumu0tXdgfrqmnBQLKX6pvX5Dry4vV-VXoay2EmudRFwJqlNAaRAqxiapKJlXGwAIziTVgU2VsqrmAXAlmQYLiMrcatEL44DjuxUsyW9dr-5pQKUCBkYiLEIxVHO0Rm6WZSSDhVqLxG5CP088uNyOlRommiJNO-VfpBGTuRLIb7Bixh4a6uS39AitTrnKNxrBChIj7UCVjYIkBxCuZRrNXBeRoEmjpl2lb7pUqIO933bjA3K2JWtt6O46JOEulCMirURF2X4KfjHhYpG_-__BD8ogjFnIu4Sg-IrOu2dq3iGU6eOcV9jf1N_bt
  priority: 102
  providerName: ProQuest
Title Natural Killer-Based Therapy: A Prospective Thought for Cancer Treatment Related to Diversified Drug Delivery Pathways
URI https://www.ncbi.nlm.nih.gov/pubmed/39065636
https://www.proquest.com/docview/3085032140
https://www.proquest.com/docview/3085120693
https://doaj.org/article/62a8c402a324425f94b05db4067c106a
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB5RuPRStYW2aWFlJMSJ0MTOy5UqxLIg1IpVVO1K3CK_Qg9oQ7PZtvn3HTvJrirBgasT5zXj-PvGnm8AjhDSyiAVkc9wevUjVZZ-ltm4leYhTalW0uWt3UyT63n07Ta-3YJBUKH_gMtHqZ2tJzWv70___mrPcMB_tYwTKfvnh5-b6O_SCqYhS-cvYIdGSNbtbr4e8bufM7NOzN1aM7f11Sjr8nqevtJ_M5YT9n8ajbpZ6eo1vOrhJDnv7P8GtsziLRzn3Q3aEzLbpFctT8gxyTdK1e0u_J4KJ7tBvruMQH-MU5ru-7RfyDnJ62pIxcRmW9CnIYhyyYX1lZrMhl3qxO2pw75NRSbdTo8SsS2Z1Ks7MjH3tqklOaLNP6Jd7sH86nJ2ce33hRh8RbOw8SW6G1NKskRGOixLHpdpII0MdGy0NInQJlGUyUywwEguBeWZUVIJxBZWAJ-9g-1FtTAfgHAmhdQcQRMitZIiWTFpkupYxtRwZMYenA4fu3jo9DYK5CnWOsWj1vFgbE2yPtnKZbuGqr4r-tFXJFRkCpmyQPiIP6mSRzKItUQwkyrkxMKD_cGgxeCCBbNqfraOU-DB4fowjj67pCIWplp154Q0SDjz4H3nCOsnwUdGsMySj899pU_wkiJ0shHkMNqH7aZemQOEPo0cwc74cpr_GLnQwci59j8TNgcn
link.rule.ids 315,783,787,867,2109,2228,21400,24330,27936,27937,33756,33757,43817,74636
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagPcAFUZ6BthgJ9dTQxM7LXKput9VC21WEtlJvkcd2ygFtliQLyr9nnDi7QgKujp1YmbH9zXjmG0I-IKSFIJWRz_F49SNVln6WWb-VFiFLmVbQ563dzJPZbfTlLr5zDrfGhVWOe2K_UetKWR_5CbfcaraqTnC6-uHbqlH2dtWV0HhIdi1VFRpfu5OLef5142UJuNVZMaTucLTvT1bftq7ixrKroUkv_jiUeu7-fwPO_uC5fEqeOMRIzwYR75EHZvmMHOXDB7pjuthmUDXH9IjmWzLq7jn5OZc9swa96pP-_AmeWtqN6T7RM5rX1Zhtic22Zk9LEcjSc6sONV2Mgei0D5vDsW1Fp0MwR4nwlU7r9T2dmu-2qaM5AspfsmtekNvLi8X5zHe1FnzFsrD1ATWKKwU8gUiHZSniMg3AQKBjo8EkUptEMQ6Z5IEBAZKJzChQEuGD5bjnL8nOslqa14QKDhK0QFyEYKxkaI-YNEl1DDEzAo1fj3wcf3axGig1CjRFrHSKv0rHIxMrkk1ny4jdN1T1feEWWJEwmSk0hiUiRNyHShFBEGtAvJIqNHulR_ZHgRZumTbFVqk88n7zGBeYvTWRS1Othz4hCxLBPfJqUITNTHDKiId58ub_L39HHs0WN9fF9ef51VvymCEusu7hMNonO229NgeIa1o4dMr7G9SY-ec
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcEG9SChgJ9dSwiZ2XuaBut6tCYRWhrdRb5FfKAW22SRaUf884cXaFBFwdO7EyY_ub8cw3AO8Q0sogFZHP8Hj1I1WWfpZZv5XmIU2pVrLPW_u6TC6uos_X8bWLf2pcWOW4J_Ybta6U9ZFPmeVWs1V1gmnpwiLy-eLj5ta3FaTsTasrp3EXDlLLgjWBg9n5Mv-287gEzOovH9J4GNr60833vdu4sUxraN7zPw6onsf_3-CzP4QWD-GBQ4_kdBD3I7hj1o_hOB8-0J2Q1T6bqjkhxyTfE1N3T-DnUvQsG-SyTwD0Z3iCaTem-0BOSV5XY-YlNtv6PS1BUEvOrGrUZDUGpZM-hA7HthWZD4EdJUJZMq-3N2RuftimjuQILn-JrnkKV4vz1dmF7-ou-IpmYetL1C6mlGSJjHRYljwu00AaGejYaGkSoU2iKJOZYIGRXArKM6OkEgglLN89ewaTdbU2L4BwJoXUHDESArOSom1i0iTVsYyp4WgIe_B-_NnFZqDXKNAssdIp_iodD2ZWJLvOlh27b6jqm8IttiKhIlNoGAtEi7gnlTySQawlYpdUoQksPDgaBVq4JdsUewXz4O3uMS42e4Mi1qbaDn1CGiScefB8UITdTHDKiI1Zcvj_l7-Be6i3xZdPy8uXcJ8iRLKe4jA6gklbb80rhDitfO109zdQMP4b
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Killer-Based+Therapy%3A+A+Prospective+Thought+for+Cancer+Treatment+Related+to+Diversified+Drug+Delivery+Pathways&rft.jtitle=Pharmaceutics&rft.au=Zang%2C+Jing&rft.au=Mei%2C+Yijun&rft.au=Zhu%2C+Shiguo&rft.au=Yin%2C+Shaoping&rft.date=2024-07-14&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=16&rft.issue=7&rft.spage=939&rft_id=info:doi/10.3390%2Fpharmaceutics16070939&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_pharmaceutics16070939
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon